Jmac Enterprises LLC Takes Position in Becton, Dickinson and Company (NYSE:BDX)

Jmac Enterprises LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,121 shares of the medical instruments supplier’s stock, valued at approximately $481,000.

Several other institutional investors also recently bought and sold shares of the stock. Sound Income Strategies LLC lifted its position in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Tompkins Financial Corp raised its holdings in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the last quarter. Birch Capital Management LLC boosted its position in Becton, Dickinson and Company by 0.4% during the 3rd quarter. Birch Capital Management LLC now owns 11,773 shares of the medical instruments supplier’s stock valued at $2,838,000 after buying an additional 48 shares during the period. Radnor Capital Management LLC boosted its position in Becton, Dickinson and Company by 1.7% during the 3rd quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 48 shares during the period. Finally, Wesbanco Bank Inc. increased its position in shares of Becton, Dickinson and Company by 1.9% in the fourth quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after acquiring an additional 48 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Piper Sandler increased their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Stock Down 0.0 %

BDX stock opened at $229.50 on Wednesday. The company has a market capitalization of $66.56 billion, a price-to-earnings ratio of 38.12, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.13. The business’s 50 day moving average price is $232.20 and its two-hundred day moving average price is $233.99. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.81%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 69.10%.

Becton, Dickinson and Company announced that its board has approved a share buyback plan on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In related news, EVP Roland Goette sold 638 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the transaction, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. The trade was a 4.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Shan sold 500 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,844 shares of company stock worth $2,210,716. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.